Company / Capital Expenditures
Summit Therapeutics Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$657.0K
FY2025
5-year range
$128.0K / $657.0K
FY2021-FY2025
Trend
+372.7%
vs FY2024
Sector context
#132 of 194
Health Care
What the data says
Capital Expenditures changed +373% YoY in FY2025, a notable deviation from the 7-year average annual change of +62%.
Based on SEC 10-K filings.
$657,000 in FY2025 with a 5-year CAGR of +9.3%.
Improved from $128,000 to $657,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +29.0%
- 5-Year CAGR
- +9.3%
- 10-Year CAGR
- -
Sector benchmark
#132 of 194 in Health CareTop 68% of 194This company $657.0K Sector average $117.5M
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.3%, indicating consistent growth.
- In FY2025, capital expenditures increased 372.7% year-over-year.
- Ranks #132 out of 194 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $657.0K | +372.7% |
| FY2024 | $139.0K | +8.6% |
| FY2023 | $128.0K | -58.2% |
| FY2022 | $306.0K | +0.0% |
| FY2021 | $306.0K | -27.3% |
| FY2020 | $421.0K | +105.4% |
| FY2019 | $205.0K | +30.6% |
| FY2018 | $157.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026